Where does omega oxidation of fatty acids occur?
The primary site of lipogenesis is:
Which molecule serves as the ultimate source of acetyl groups for fatty acid synthesis?
Which of the following is a true difference between gangliosides and cerebrosides?
Chylomicron remnants are associated with ?
Apo-E deficiency is seen in which of the following conditions?
What is the rate-controlling enzyme of fatty acid synthesis?
Which lipoprotein level is affected by LCAT deficiency?
Which enzyme is primarily responsible for the fat metabolism in adipose tissue?
In which condition does serum appear milky white?
Explanation: ***Endoplasmic Reticulum*** - **Omega oxidation** of fatty acids occurs in the **endoplasmic reticulum (microsomes)** of liver and kidney cells. - This pathway involves **hydroxylation of the terminal omega carbon** by **cytochrome P450 enzymes** located in the smooth ER. - The omega carbon is then oxidized to a **carboxyl group**, forming a **dicarboxylic acid**. - This is a **minor pathway** that becomes important when **beta-oxidation is impaired** or for metabolism of **medium-chain fatty acids**. *Cytosol* - The cytosol is involved in **fatty acid synthesis**, not omega oxidation. - While some later steps of fatty acid metabolism occur in the cytosol, the initial hydroxylation step of omega oxidation requires ER-localized cytochrome P450 enzymes. *Mitochondria* - **Mitochondria** are the primary site for **beta-oxidation** of fatty acids, not omega oxidation. - Beta-oxidation sequentially removes **two-carbon units from the carboxyl end**, which is distinct from omega oxidation. - The dicarboxylic acids produced by omega oxidation may subsequently undergo beta-oxidation in mitochondria. *None of the options* - This option is incorrect because the endoplasmic reticulum is the correct cellular location for omega oxidation. - The ER contains the necessary cytochrome P450 enzymes for the hydroxylation reaction that initiates this pathway.
Explanation: ***Liver*** - The **liver** is the principal organ for **de novo lipogenesis**, converting excess carbohydrates into fatty acids and triglycerides. - This process is highly active in response to a high-carbohydrate diet, with the synthesized lipids packaged into **VLDL** for transport. *Skeletal muscles* - **Skeletal muscles** primarily utilize fatty acids for **energy production** rather than synthesizing large amounts of new lipids. - While they can store some triglycerides, their capacity for de novo lipogenesis is significantly lower compared to the liver. *Myocardium* - The **myocardium** (heart muscle) primarily relies on fatty acids for its continuous **energy demands** and has limited capacity for de novo lipogenesis. - Its metabolic focus is on efficient **ATP generation** to maintain cardiac function. *Lungs* - The **lungs** are not a primary site for general lipogenesis, though they are involved in the synthesis of specific lipids like **surfactant**. - Surfactant synthesis is a specialized process crucial for lung function, distinct from general energy storage lipogenesis.
Explanation: ***Acetyl CoA*** - **Acetyl CoA** is the ultimate source of all acetyl groups used in fatty acid synthesis - It serves as the substrate for **acetyl CoA carboxylase**, which converts it to **malonyl CoA** - After transport from mitochondria via **citrate**, acetyl CoA is the precursor for all two-carbon units incorporated into fatty acids - One molecule of acetyl CoA also serves as the primer for fatty acid synthesis *Malonyl CoA* - **Malonyl CoA** is the direct two-carbon donor to the growing fatty acid chain - However, it is derived from **acetyl CoA** through carboxylation by **acetyl CoA carboxylase** - It is an intermediate, not the ultimate source of acetyl groups *Palmitate* - **Palmitate** is a 16-carbon saturated fatty acid that is the end product of de novo fatty acid synthesis - It is the product of fatty acid synthesis, not a donor of acetyl groups *Citrate* - **Citrate** transports acetyl groups from the **mitochondria** to the **cytosol** where fatty acid synthesis occurs - In the cytosol, **ATP citrate lyase** cleaves citrate back into **acetyl CoA** and oxaloacetate - Citrate is a transport vehicle, not the ultimate source of acetyl groups
Explanation: ***Charge difference*** - **Gangliosides** contain **sialic acid (N-acetylneuraminic acid)** residues, which are negatively charged, making gangliosides **anionic**. - **Cerebrosides** are **neutral glycosphingolipids** as they lack charged sugar residues. *Specific carbohydrate composition* - While both have carbohydrate components, referring to "specific carbohydrate composition" as the *true difference* is too broad. Both have characteristic sugar groups, but the **presence of sialic acid** in gangliosides is the key differentiator in charge. - Cerebrosides typically contain a single sugar (either glucose or galactose), whereas gangliosides have a more complex oligosaccharide chain including sialic acid. *Presence of glucose* - Both cerebrosides (specifically **glucocerebrosides**) and gangliosides can contain **glucose** in their carbohydrate moieties. - This is not a distinguishing feature; the *type* and *arrangement* of sugars, particularly the presence of sialic acid, are more specific. *Location in the nervous system* - Both gangliosides and cerebrosides are abundant in the **nervous system**, particularly in cell membranes. - Their presence in the nervous system is a similarity, not a differentiating factor.
Explanation: ***Apo-E*** - **Apolipoprotein E (Apo-E)** is a crucial apolipoprotein on the surface of chylomicron remnants, acting as a **ligand for the LDL receptor-related protein 1 (LRP1)** in the liver. - This binding facilitates the **hepatic uptake and clearance** of chylomicron remnants from circulation. *Apo-A* - **Apo-AI** is the primary apolipoprotein of **HDL** and plays a key role in reverse cholesterol transport by activating **lecithin-cholesterol acyltransferase (LCAT)**. - While chylomicrons *acquire* some Apo-AI from HDL, it is not the primary apolipoprotein defining their remnants' hepatic clearance. *Apo-C* - **Apo-CII** is a vital activator of **lipoprotein lipase (LPL)**, which metabolizes triglycerides in chylomicrons and VLDL. - **Apo-CIII** inhibits LPL and hinders receptor-mediated uptake, but **Apo-E** is the key for remnant recognition and uptake, not Apo-C in general. *Apo-B100* - **Apo-B100** is the main structural apolipoprotein of **LDL** and **VLDL**, serving as the ligand for the LDL receptor, mediating their hepatic uptake. - While chylomicrons have **Apo-B48**, which is a truncated form of Apo-B100, Apo-B100 itself is not found on chylomicron remnants.
Explanation: ***Type III hyperlipoproteinemia*** - This condition, also known as **familial dysbetalipoproteinemia** or **broad beta disease**, is characterized by a deficiency or abnormal function of **apolipoprotein E (apoE)**. - The deficiency in functional apoE impairs the clearance of **chylomicron remnants** and **intermediate-density lipoproteins (IDLs)** from the blood. *Type II hyperlipoproteinemia* - This condition primarily involves elevated **LDL cholesterol** and is often due to defects in the **LDL receptor** or mutations in **apoB-100**, not apoE deficiency. - It does not directly involve the impaired clearance of chylomicron remnants or IDLs. *Type I hyperlipoproteinemia* - Also known as **familial chylomicronemia syndrome**, this condition is characterized by severe elevation of **chylomicrons** and **triglycerides**. - It is caused by a deficiency of **lipoprotein lipase (LPL)** or its cofactor **apoC-II**, not apoE. *Type IV hyperlipoproteinemia* - This condition, also known as **familial hypertriglyceridemia**, is characterized by abnormally high levels of **very-low-density lipoproteins (VLDL)** and **triglycerides**. - It is typically caused by increased VLDL production or impaired VLDL clearance, but not directly due to an apoE deficiency.
Explanation: ***Acetyl-CoA carboxylase*** - **Acetyl-CoA carboxylase (ACC)** catalyzes the committed step in fatty acid synthesis, converting **acetyl-CoA** to **malonyl-CoA**. - This enzyme is subject to both allosteric regulation (e.g., activation by **citrate** and inhibition by **long-chain fatty acyl-CoA**) and hormonal regulation (e.g., phosphorylation by glucagon and dephosphorylation by insulin). *Thioesterase* - **Thioesterase** is the enzyme responsible for releasing the completed fatty acid chain from the **fatty acid synthase complex**. - While essential for the termination of synthesis, it does not regulate the initiation or overall rate of the pathway. *Transacetylase* - **Transacetylase** (specifically, acetyl-CoA-ACP transacetylase and malonyl-CoA-ACP transacetylase) is involved in transferring acetyl and malonyl groups to the **acyl carrier protein (ACP)** within the fatty acid synthesis complex. - This is an intermediary step, but not the primary **rate-controlling** or committed step. *Ketoacyl synthase* - **Ketoacyl synthase (or β-ketoacyl-ACP synthase)** is responsible for condensing the growing acyl chain with malonyl-ACP, leading to the formation of a **β-ketoacyl-ACP**. - This is a crucial chain elongation step within the fatty acid synthase complex, but not the enzyme that controls the overall commitment to fatty acid synthesis.
Explanation: ***HDL*** - **LCAT (Lecithin-cholesterol acyltransferase)** is crucial for the maturation of **HDL (High-Density Lipoprotein)**. - LCAT esterifies cholesterol in HDL, enabling it to accept more free cholesterol from peripheral tissues, thus a deficiency leads to dysfunctional and decreased mature HDL. *LDL* - **LDL (Low-Density Lipoprotein)** formation primarily involves the breakdown of VLDL and IDL by lipoprotein lipase and hepatic lipase, not directly LCAT activity. - While an LCAT deficiency can indirectly affect lipid metabolism, its direct impact on LDL levels is less pronounced compared to HDL. *VLDL* - **VLDL (Very-Low-Density Lipoprotein)** is synthesized in the liver and transports triglycerides, with its metabolism being largely independent of LCAT. - LCAT's primary role is in **reverse cholesterol transport** and HDL maturation, not VLDL synthesis or catabolism. *Chylomicron* - **Chylomicrons** are formed in the intestines and transport dietary triglycerides and cholesterol, with their metabolism involving lipoprotein lipase. - LCAT does not directly affect the synthesis or breakdown of chylomicrons, which are primarily concerned with exogenous lipid transport.
Explanation: ***Hormone-sensitive lipase*** - This enzyme is crucial for the **mobilization of stored triglycerides** in adipose tissue by hydrolyzing them into fatty acids and glycerol. - Its activity is stimulated by hormones like **epinephrine** and **norepinephrine** and inhibited by insulin, reflecting its role in regulating fat release during energy demand. *Lipoprotein lipase* - This enzyme is primarily located on the **endothelial surface of capillaries** in various tissues, including adipose tissue, muscle, and heart. - Its main role is to clear **triglyceride-rich lipoproteins** like chylomicrons and VLDL from the bloodstream, facilitating the uptake of fatty acids into cells for storage or energy, rather than direct fat metabolism within the adipose cell. *Acid lipase* - **Lysosomal acid lipase** functions within lysosomes to break down cholesterol esters and triglycerides that are taken up by cells. - Its primary role is in the degradation of lipids within the **lysosomal compartments**, not in the primary process of fat mobilization from adipose tissue stores. *Acid maltase* - Also known as **alpha-glucosidase**, this enzyme is a lysosomal enzyme responsible for breaking down glycogen into glucose. - Its function is related to **glycogen metabolism** and has no direct role in fat metabolism in adipose tissue.
Explanation: ***Increased Chylomicrons*** - **Chylomicrons** are the largest lipoprotein particles (75-1200 nm) with the highest **triglyceride content (85-95%)**, giving serum a characteristic **milky white** or "creamy" appearance - This intense milky appearance occurs after **fatty meals** (postprandial lipemia) or in **Type I and V hyperlipidemias** (familial chylomicronemia syndrome) - The **light scattering** by these large particles makes the serum completely opaque, distinguishing it from other lipid abnormalities - Classic clinical finding: **"cream layer" forms on top** when lipemic serum stands overnight in refrigerator *Increased LDL* - Elevated **Low-Density Lipoprotein (LDL)** produces **clear to slightly hazy** serum, never milky white - LDL particles are much smaller (18-25 nm) than chylomicrons and contain primarily **cholesterol**, not triglycerides - High LDL is a cardiovascular risk factor but does not cause visible lipemia *Increased HDL* - **High-Density Lipoprotein (HDL)** elevation results in **clear serum** - HDL particles are the smallest (5-12 nm) and densest lipoproteins - High HDL is protective and causes no turbidity *Increased VLDL* - **Very Low-Density Lipoprotein (VLDL)** elevation can cause **turbid or hazy** serum in severe hypertriglyceridemia, but typically less intensely milky than chylomicrons - VLDL particles are smaller (30-80 nm) than chylomicrons with lower triglyceride content (50-65%) - In Type IV hyperlipidemia (isolated VLDL elevation), serum appears uniformly turbid without cream layer formation - The most dramatic "milky white" appearance is specifically associated with **chylomicronemia**
Lipid Classification and Chemistry
Practice Questions
Fatty Acid Oxidation
Practice Questions
Ketone Body Metabolism
Practice Questions
Fatty Acid Synthesis
Practice Questions
Metabolism of Triacylglycerols
Practice Questions
Phospholipid Metabolism
Practice Questions
Cholesterol Metabolism and Biosynthesis
Practice Questions
Bile Acids and Bile Salts
Practice Questions
Lipoprotein Metabolism and Transport
Practice Questions
Dyslipidemias and Atherosclerosis
Practice Questions
Prostaglandins and Eicosanoids
Practice Questions
Fatty Liver and Lipotropic Factors
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free